
Not your average farmer. Winners always win. My music @TheUrbanFarmer(all platforms) most songs https://teapawt.net/t.co/wuKdH0WLVV dm 4 discord inv
Based City, USA.
Joined January 2022
- Tweets3.3K
- Following95
- Followers1.3K
- Likes10.4K
Pinned Tweet
The American people deserve the truth.
FDA, do you remember Covaxin? The traditional whole-virion vaccine that you forced to jump through every bureaucratic hoop, while you were fast-tracking mRNA boosters based on trials conducted on just 8 mice? You urged the company to seek approval through a U.S. BLA trial, and they did—spending over $100 million on a massive Phase 3 trial that yielded top-line data showing broad protection against all variants of concern. Yet, despite this, you never approved an alternative traditional vaccine option after they successfully navigated your obstacle course. Why? Because just months after those results were published, you changed the rules to block any vaccine built on the original virus. This effectively killed the market for traditional vaccines based on the whole coronavirus. Meanwhile, you rolled out the next set of mRNA boosters, designed to mimic just a tiny piece of the spike protein on a virus that’s famously studied for its high mutation rates.
It’s been four long years, and you still haven’t approved any competitor vaccines. The government collects royalties from mRNA sales, with companies like Moderna paying over $400 million in a single year. But those profits wouldn’t roll in from a traditional vaccine sale, would they? How has this financial entanglement influenced your decision-making during the pandemic?
Your job is to serve the public—to prioritize science and protect the American people. But you’ve failed in that duty. Instead, you’ve used taxpayer dollars to accelerate only the development of “vaccines” that you own patents on, blocking all competitor vaccines for over four years. Do you really think the American people will trust that this next round of mRNA boosters will finally work, after six previous rounds failed to deliver?
Your actions have severely damaged your credibility. Government entities should never receive kickbacks from the sales of drugs they’re responsible for approving. This is an egregious conflict of interest, and we’re living with the consequences. The amount of blood on your hands is staggering. Next-generation vaccines that have been proven to stop transmission are approved overseas, yet Americans have no choice but to take this mRNA snake oil.
This is the biggest scam our country has ever seen. It’s time for real journalism to uncover the truth. There must be accountability, and the American people deserve to know who the main perpetrators are.
Rest in peace to all those lost in this pandemic due to this corruption.
$OCGN is targeting some of the biggest markets in biotech, with remarkable efficacy, a exceptional safety profile, hundreds of genetic mutations addressed with a single therapy, markets with little to no effective treatment options, a platform set to keep expanding with back to back pivotal results and commercialization right around the corner.
The markets are what they are, the numbers are what they are. Hell, I was breaking down these drugs numbers years ago showcasing the trillion dollar market potential you’re now seeing presented on the company’s slides.
My point is, if you’re buying this stock today, you’re buying what is clearly going to become one of the largest and most profitable biotech companies in history, before everyone else realizes it.
If you’ve ever wondered what it would’ve been like to buy into one of the giants of an industry at the ground floor, right before the steady rise to market leaders, well, you’re looking at one of those opportunities right now. It’s beyond obvious. 🍻
$ocgn Most will see “Phase 3 for GA in 2026” and shrug. The ones who know GA, the therapy and this market understand the gravity of what was just announced.
Dr. Jay Chhablan the Vice Chair of Clinical Trials at the University of Pittsburgh Medical Center Vision Institute just said the 6 month OCU410 data already looks superior to the FDA approved drugs when he compared them side by side.
Retail needs to understand why this sets OCU410 up as one of the most valuable medicines ever lined up to hit the market.
Why I’m saying that
OCU400 family keeps winning. OCU400 for IRDs, OCU410ST for Stargardt, and OCU410 for GA have shown consistent 100% efficacy signals with 100% safety to date. FDA’s recent CGT flexibility on self controlled designs external controls and registry follow up is also built for this platform and means a very fast path to market than anyone expects.
So why would OCU410 likely be the world’s most valuable drug and why has big pharma paid billions for early phase GA assets?
Because the numbers are staggering.
👇🍻💸🏦
Today, at the @Stifel 2026 Healthcare Conference, Ocugen CEO @drsmusunuri highlighted our novel modifier #genetherapy platform and three Phase 3 investigational assets in NYC. #Biotech
Watch the replay: bit.ly/4zdvc2f
$OCGN
TheUrbanFarmer retweeted
$OCGN
Disruptive. What a fitting word. Brilliant conference @drsmusunuri . Congratulations to you and team Ocugen!
Today, at the @Stifel 2026 Healthcare Conference, Ocugen CEO @drsmusunuri highlighted our novel modifier #genetherapy platform and three Phase 3 investigational assets in NYC. #Biotech
Watch the replay: bit.ly/4zdvc2f
$OCGN
$OCGN People see that Celairis isn’t a giant, lacks doctors or labs, and assume they can’t do anything.
Reality is, a guy with RP walks into an ophthalmology office, doc says there’s an approved treatment, and he goes to a local surgeon to get dosed.
These aren’t development partnerships, they’re licensing deals. Ocugen retains control/sole manufacturing rights. Celairis gets OCU400 approved in their territory.
The question isn’t whether Celairis can manufacture or perform surgery. It’s whether they can get us approved.
Their CEO spent 11 years at Novartis as Country President for Australia/New Zealand, then ran Australia’s largest pharma company. I’d say he’s exactly who we need.
Ocugen isn’t selling out to BP. They know what they own, have commercial supply ready, and their drug uses existing surgical techniques.
The outcome is thousands of million dollar checks coming in globally for Ocugen to collect for the next 10+ years. 🍻
$OCGN once again expanded its global reach while retaining a significant share of future profits. 50% of gross profits plus royalties. The company is set up to collect checks in the mail to the tune of billions yearly. 🍻
$OCGN If it isn’t painfully obvious by now, all the doom and gloom narratives constantly spread about this company always ends up fading into irrelevance. And it’s because the science here always speaks louder than the noise, and it’s screaming the next big pharma.
Fuck fuck fuck the noise, fam. 🍻
TheUrbanFarmer retweeted
New Research Report: Ocugen (OCGN) – 3Q26 Reported With Expected Progress In All Three Trials
$OCGN #Ocugen #Investing #EquityResearch
channelchek.com/news-channel…
$OCGN We’re talking about a pre Rev biotech that’s just months away from pivotal results. If you bought this stock but didn’t buy it for the catalyst, then what exactly were you buying it for, and why have you held this whole time?
Over the past year, the stock has ranged from $0.70-$2.50. If SP was your whole reason for buying, could’ve sold at $2.50. But if you actually bet on the products, then buck up buttercup. The current price range is about to be completely irrelevant.
Examples of pre rev biotechs heading into pivotal Phase 3 results:
1. ABVX (2025)
Bled 72% before Phase 3 results.
Then went from $4.77 to $148.83.
2. CPXX (2016)
Bled 64% before Phase 3 results.
Then went from $1.12 to $30.36.
3. CELC (2025)
Bled 66% before Phase 3 results.
Then went from $7.58 to $120.32.
If this platform validates itself the way the evidence increasingly suggests it will, we’re talking about a market opportunity that makes all those examples look insignificant. 🍻
🤖 Made with AI
TheUrbanFarmer retweeted
$OCGN #OCUGEN @Ocugen @drsmusunuri .... love seeing patient after patien seeing the improvements.
Thank you @Ocugen team!!!
$OCGN The drugs are everything, and nearly every single piece of evidence we see suggests the trials are going damn well. Hearing patient after patient describe their improvements, and now over a year after treatment hearing them say they’re still seeing improvements, is exactly what an investor wants to see with phase 3 results just months away.
If this is the norm for people in the trial/EAP, the results will be beyond stellar and well beyond what’s needed to meet the primary endpoint. We’re going from having money riding on a speculative biotech to owning a piece of the next big pharma. 🍻
$OCGN The drugs are everything, and nearly every single piece of evidence we see suggests the trials are going damn well. Hearing patient after patient describe their improvements, and now over a year after treatment hearing them say they’re still seeing improvements, is exactly what an investor wants to see with phase 3 results just months away.
If this is the norm for people in the trial/EAP, the results will be beyond stellar and well beyond what’s needed to meet the primary endpoint. We’re going from having money riding on a speculative biotech to owning a piece of the next big pharma. 🍻
Ocugen is taking part in two key industry events this November!
CEO @drsmusunuri will participate in the Stifel 2026 Healthcare Conference and Cell & Gene Leaders Live 2026. Read more: bit.ly/4ss67Pm
#HealthcareInnovation #GeneTherapy $OCGN
Today, FDA kicked off its Rare Disease Framework Initiative with a public meeting, co-hosted by @ReaganUdall. Thanks to all who joined for your input, candor & vision. With only 5% of rare diseases having an approved treatment, the status quo isn't enough — we must do more.
FDA Acting Commissioner @FDA_KyleD shared with the attendees that the “urgency of the need has not changed, but now we — the agency, drug developers, researchers, and patients — are ready to meet that need together.”
TheUrbanFarmer retweeted
Cell and gene therapies can change what’s possible for patients living with rare and severe diseases. Cost shouldn’t put that possibility out of reach.
CMS is expanding our Cell and Gene Therapy Access Model to help more Medicaid patients access these life-changing treatments. Learn more about the CGT 2.0 Model: go.cms.gov/CGT
At Cleveland Clinic today, CMS Innovation Center Director Abe Sutton, @DrOzCMS, and @FDA_KyleD announced that CMS will invite manufacturers of other cell and gene therapies to apply to the CGT Access Model. Learn more: go.cms.gov/CGT
$OCGN fam, in roughly 20 days we will see good OCU410ST interim results. Roughly 30 days after that we will see OCU400’s Bahamas approval/first commercial patient dosed.
This SP bleed is absurd yet an incredible opportunity to accumulate more.
Institutional ownership continues to climb, with it comes more votes as per the new record date changing from July 26 to October 30th, great interim results, followed by the vote passing which makes our books flip from -$25M under liabilities to +$90M over liabilities, then boom we don’t look like a horrible buy anymore right on time for the Bahamas full approval news with first commercial revenue, then the hype train leading up to top line phase 3 results.
SP might be annoying af to look at right now, but the bearishness here is a fugazi with plenty of real substance coming soon. 🍻
TheUrbanFarmer retweeted
$ocgn does anyone else really compare Ocugen?
Not really, the industry is full of single asset gene therapy companies trying to secure a niche and maybe make a billion.
A good comparison is to look back at early Vertex/early Regeneron. Those were platform companies that built dominance around a biological insight that could be applied across multiple indications.
Ocugen isn’t a single asset gene therapy company. They aren’t chasing one mutation. They’re a platform company. Their nuclear hormone receptor platform regulates an entire genetic network connected to countless diseases. OCU400 is what will prove this biological insight. It won’t just mean one product approval, it validates the platform.
Ocugen has 3 BLAs lined up over the next two years. Manufacturing in place, commercial supply stored, strategic global partnerships, and patents filed to later expanding the platform, neurodegenerative diseases patents, including four Alzheimer’s patents.
This isn’t some niche ophthalmology company. It’s a vertically integrated gene therapy company with repeatable applications across massive unmet markets, at a time when regulatory pathways are evolving to fast track these exact kinds of indications.
If data continues like it has, we’re looking at the next big pharma without a doubt. And the revenue Ocugen is staring at likely means future forward splits, dividends, and buybacks.
The question isn’t “who do we become?” It’s what is a validated gene agnostic modifier platform worth? And I can tell you, its future is worth a hell of a lot more than Vertex and Regeneron combined. 🍻




































